• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis.

作者信息

Riva E, Fossali E, Bettinelli A

出版信息

Eur J Clin Pharmacol. 1982;21(4):303-6. doi: 10.1007/BF00637617.

DOI:10.1007/BF00637617
PMID:7056274
Abstract

Furosemide was measured by gas-liquid chromatography in blood and dialysis fluid from 7 children with chronic renal failure, undergoing regular haemodialysis. It was administered chronically, in two or three daily doses (4.2-9.4mg/kg). Two children received 1 mg/kg intravenously for determination of the pharmacokinetics. The half-life was longer than in adults and in anephric patients on haemodialysis. Systemic and renal clearance were also much lower. Plasma protein binding in 2 out of 6 cases was reduced as compared to normal adults. The data do not suggest any need to modify the present dosage schedule despite the 4-5 fold increase in the half-life of furosemide. The contribution of haemodialysis to drug clearance was minimal, and accounted for less than 10% of the total clearance.

摘要

相似文献

1
Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis.
Eur J Clin Pharmacol. 1982;21(4):303-6. doi: 10.1007/BF00637617.
2
Elimination of furosemide in healthy subjects and in those with renal failure.
Clin Pharmacol Ther. 1977 Jul;22(1):70-8. doi: 10.1002/cpt197722170.
3
[Kinetics of furosemide in children with chronic renal insufficiency in dialysis].[慢性肾功能不全透析儿童中呋塞米的药代动力学]
Minerva Nefrol. 1980 Jul-Sep;27(3):409-11.
4
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.奥硝唑在肾功能不全患者中的药代动力学;血液透析和腹膜透析的影响。
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
5
Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.严重肾衰竭和血液透析对左西孟旦及其代谢产物药代动力学的影响。
Clin Pharmacokinet. 2007;46(3):235-46. doi: 10.2165/00003088-200746030-00004.
6
An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole.肾功能损害及血液透析对氟康唑药代动力学影响的评估
Br J Clin Pharmacol. 1990 Feb;29(2):221-6. doi: 10.1111/j.1365-2125.1990.tb03623.x.
7
Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.替硝唑在慢性肾衰竭患者及血液透析患者中的药代动力学
Br J Clin Pharmacol. 1983 Jun;15(6):735-41. doi: 10.1111/j.1365-2125.1983.tb01558.x.
8
Furosemide kinetics in renal failure.肾衰竭时呋塞米的动力学
Clin Pharmacol Ther. 1978 Jun;23(6):644-50. doi: 10.1002/cpt1978236644.
9
Pharmacokinetics of furosemide in advanced renal failure.
Clin Pharmacol Ther. 1974 Oct;16(4):659-66. doi: 10.1002/cpt1974164659.
10
[Protein binding and elimination half-life of furosemide in chronic hemodialysed patients].[慢性血液透析患者中呋塞米的蛋白结合及消除半衰期]
Therapie. 1979 May-Jun;34(3):355-66.

引用本文的文献

1
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.一个用于模拟在患有心力衰竭和容量超负荷的青少年中皮下注射固定剂量呋塞米的成人群体药代动力学模型。
Clin Pharmacokinet. 2025 May 13. doi: 10.1007/s40262-025-01515-2.
2
Furosemide disposition in patients on CAPD.持续性非卧床腹膜透析患者中呋塞米的处置情况
Eur J Clin Pharmacol. 1995;48(5):385-90. doi: 10.1007/BF00194955.
3
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

本文引用的文献

1
Clinical pharmacokinetics of diuretics.利尿剂的临床药代动力学
Clin Pharmacokinet. 1980 May-Jun;5(3):221-45. doi: 10.2165/00003088-198005030-00003.
2
Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.速尿在正常受试者和功能性无肾患者中的药代动力学。
Clin Pharmacol Ther. 1974 Jun;15(6):588-96. doi: 10.1002/cpt1974156588.
3
Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically.通过荧光法测定的血清和尿液中呋塞米的浓度及其与血清蛋白的结合情况。
接受血液透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003.
4
Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
Eur J Clin Pharmacol. 1985;28(1):53-9. doi: 10.1007/BF00635708.
5
Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.呋塞米在健康与疾病状态下的药代动力学和药效学——最新进展
J Pharmacokinet Biopharm. 1989 Feb;17(1):1-46. doi: 10.1007/BF01059086.
Clin Chem. 1974 Feb;20(2):152-8.
4
Pharmacokinetics of orally administered furosemide.
Clin Pharmacol Ther. 1974 Feb;15(2):178-86.
5
Pharmacokinetics and pharmacodynamics of Lasix.
Scott Med J. 1974;19 Suppl 1:5-13. doi: 10.1177/00369330740190S103.
6
Gas chromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector.采用萃取烷基化技术和电子捕获检测器,通过气相色谱法测定血浆中的呋塞米。
J Chromatogr. 1974 Dec 4;101(1):219-21. doi: 10.1016/s0021-9673(01)94754-5.
7
Pharmacokinetics of furosemide in advanced renal failure.
Clin Pharmacol Ther. 1974 Oct;16(4):659-66. doi: 10.1002/cpt1974164659.
8
Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.血浆中呋塞米的测定及其在正常血浆和急性肾衰竭患者血浆中与蛋白质的结合情况。
Acta Pharmacol Toxicol (Copenh). 1974 Jul;35(1):49-57. doi: 10.1111/j.1600-0773.1974.tb00724.x.
9
On the fate of furosemide in man.关于速尿在人体中的代谢情况。
Eur J Clin Pharmacol. 1975 Oct 10;9(1):51-61. doi: 10.1007/BF00613429.
10
[Optimal dosage of furosemide in patients treated with repeated dialysis].[接受重复透析治疗患者的呋塞米最佳剂量]
J Urol Nephrol (Paris). 1975 Sep;81(9):697-702.